Department of Pharmacology, Faculty of Medicine, Sebha University, Sebha, Libya.
Libyan J Med. 2012;7. doi: 10.3402/ljm.v7i0.19708. Epub 2012 Nov 28.
To examine the opinions of Libyan doctors regarding the quality of drug information provided by pharmaceutical company representatives (PCRs) during detailing visits.
An anonymous survey was conducted among 1,000 doctors from selected institutes in Tripoli, Benghazi and Sebha. Doctors were asked questions regarding the quality of information provided during drug-detailing visits.
A questionnaire return rate of 61% (608 returned questionnaires out of 1,000) was achieved. The majority (n=463, 76%) of surveyed participants graded the quality of information provided as average. Approximately, 40% of respondents indicated that contraindications, precautions, interactions and adverse effects of products promoted by PCRs were never or rarely mentioned during promotional visits, and 65% of respondents indicated that an alternative drug to the promoted product was never or rarely mentioned by the representatives. More than 50% of respondents (n=310, 51%) reported that PCRs were not always able to answer all questions about their products. Only seven respondents (1%) believed that PCRs never exaggerated the uniqueness, efficacy or safety of their product. The majority of respondents (n=342, 56%) indicated that verbal information was not always consistent with written information provided. Seven per cent of respondents (n=43) admitted that they did not know whether or not the verbal information provided by PCRs was consistent with written information.
Doctors believe that the provision of drug information by PCRs in Libya is incomplete and often exaggerated. Pharmaceutical companies should ensure that their representatives are trained to a standard to provide reliable information regarding the products they promote.
调查利比亚医生对制药公司代表（PCR）在详细访问期间提供药物信息质量的看法。
在的黎波里、班加西和塞卜哈的选定机构中对 1000 名医生进行了匿名调查。医生们被问及在药物详细访问期间提供信息的质量问题。
问卷调查的回收率为 61%（1000 份中有 608 份返回的问卷）。大多数（n=463，76%）接受调查的参与者将提供的信息质量评为平均水平。大约 40%的受访者表示，PCR 在促销访问中从未或很少提及所推广产品的禁忌症、注意事项、相互作用和不良反应，65%的受访者表示，代表从未或很少提及推广产品的替代药物。超过 50%的受访者（n=310，51%）报告说，PCR 并不总是能够回答有关其产品的所有问题。只有 7 名受访者（1%）认为 PCR 从不夸大其产品的独特性、疗效或安全性。大多数受访者（n=342，56%）表示，口头信息并不总是与提供的书面信息一致。7%的受访者（n=43）承认，他们不知道 PCR 提供的口头信息是否与书面信息一致。
医生认为利比亚 PCR 提供的药物信息不完整，且经常夸大其词。制药公司应确保其代表接受培训，以提供其推广产品的可靠信息。
